285 related articles for article (PubMed ID: 10492357)
21. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
Pakos EE; Fotopoulos AD; Ioannidis JP
J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy.
Franzius C; Sciuk J; Daldrup-Link HE; Jürgens H; Schober O
Eur J Nucl Med; 2000 Sep; 27(9):1305-11. PubMed ID: 11007511
[TBL] [Abstract][Full Text] [Related]
23. Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter.
Kand PG; Tiwari BP; Basu S; Asopa RV; Nayak UN
Indian J Cancer; 2010; 47(4):380-4. PubMed ID: 21131749
[TBL] [Abstract][Full Text] [Related]
24. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
25. [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency].
Zhou LL; Wang C; Zhao JH; Yan SK; Gao YR; Cai Q; Jiang JL; Wan LP; Yang J; Wei J; Zhao M; Bai HT
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):233-6. PubMed ID: 19731822
[TBL] [Abstract][Full Text] [Related]
26. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
Fuster D; Chiang S; Andreadis C; Guan L; Zhuang H; Schuster S; Alavi A
Nucl Med Commun; 2006 Jan; 27(1):11-5. PubMed ID: 16340718
[TBL] [Abstract][Full Text] [Related]
27. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.
Daldrup-Link HE; Franzius C; Link TM; Laukamp D; Sciuk J; Jürgens H; Schober O; Rummeny EJ
AJR Am J Roentgenol; 2001 Jul; 177(1):229-36. PubMed ID: 11418435
[TBL] [Abstract][Full Text] [Related]
28. Whole body MRI with qualitative and quantitative analysis of DWI for assessment of bone marrow involvement in lymphoma.
Balbo-Mussetto A; Saviolo C; Fornari A; Gottardi D; Petracchini M; Macera A; Lario CV; Gallo T; Tarella C; Cirillo S
Radiol Med; 2017 Aug; 122(8):623-632. PubMed ID: 28421406
[TBL] [Abstract][Full Text] [Related]
29. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
[TBL] [Abstract][Full Text] [Related]
30. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
32. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma.
Lin P; Chu J; Kneebone A; Moylan E; Jalaludin B; Pocock N; Kiat H; Rosenfeld D
Intern Med J; 2005 Feb; 35(2):91-6. PubMed ID: 15705137
[TBL] [Abstract][Full Text] [Related]
33. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
34. Extranodal malignant lymphoma: detection with FDG PET versus CT.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.
Bangerter M; Kotzerke J; Griesshammer M; Elsner K; Reske SN; Bergmann L
Acta Oncol; 1999; 38(6):799-804. PubMed ID: 10522771
[TBL] [Abstract][Full Text] [Related]
36. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
37. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
38. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
39. Staging and monitoring of malignant lymphoma of the bone: comparison of 67Ga scintigraphy and MRI.
Stroszczynski C; Oellinger J; Hosten N; Spahn G; Amthauer H; Ricke J; Hoffmann KT; Eichstaedt H; Ludwig WD; Felix R
J Nucl Med; 1999 Mar; 40(3):387-93. PubMed ID: 10086700
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma.
Rini JN; Leonidas JC; Tomas MB; Palestro CJ
J Nucl Med; 2003 Jul; 44(7):1072-4. PubMed ID: 12843223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
